Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
about
Characterization of nuclear localization and SUMOylation of the ATBF1 transcription factor in epithelial cellsImplication of snoRNA U50 in human breast cancerEmerging directions in the genetics of atrial fibrillationBehavioral abnormalities observed in Zfhx2-deficient mice.Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancerAdditive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic TumorigenesisDeletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH.Selection of thermodynamic models for combinatorial control of multiple transcription factors in early differentiation of embryonic stem cellsATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphismLoss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancerSignatures of Archaic Adaptive Introgression in Present-Day Human Populations.Novel genetic targets in endometrial cancer.SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancerATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasisCopy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumorsEpigenetics of prostate cancer: beyond DNA methylationAtbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling.Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathwaysGenome-wide association studies of atrial fibrillation: past, present, and future.Genetics of atrial fibrillation: implications for future research directions and personalized medicine.Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer.Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cellsChromosome 16q22 variants in a region associated with cardiovascular phenotypes correlate with ZFHX3 expression in a transcript-specific mannerBeta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons.Copy number alterations in prostate tumors and disease aggressivenessEpigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells.Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas.Heterozygous deletion of Atbf1 by the Cre-loxP system in mice causes preweaning mortalityChromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancerThe Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.Atbf1 is required for the Pit1 gene early activationGenetic mechanisms of atrial fibrillation: impact on response to treatmentZinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling ActivityGenetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
P2860
Q24339436-23E5A334-062B-41F9-89C2-766F84CF89B7Q24594639-50A1C76B-50CC-4B63-B576-9D60CD485C13Q26852051-CBE68BAA-01C5-4387-BAC3-F74AE13F9D4FQ27323021-408978AB-A74B-43C7-8D06-C6B975B5C128Q28266601-9D26D954-517B-4B8D-A045-6275195AE86AQ30278925-7BCB2F44-92DA-425D-BDAB-5150604A80F9Q30410016-702E13D2-12A7-4D2B-80AF-6EF5568A6225Q33280495-FC51FDBF-028C-40B4-954B-F3F6A76D68C1Q33325602-55E4FADE-678F-4365-8457-823E33D57770Q33328665-163B80CA-CFFB-410F-9CA9-587B6D5B6E61Q33369969-910F94EA-E90A-4494-898C-C7EEF60367DEQ33590851-EC806CF6-600F-4C01-8A40-6FC061ACEE3CQ34026696-49EC483A-9950-4A5B-9C55-4254E3873FC6Q34071777-49A4FDBD-275F-426F-8DE4-1851E82B567EQ34236787-4B14A2E9-CBA4-435E-9331-EC965623BC54Q34326537-E136BC90-ED34-46E4-B017-C8543820655EQ34452275-CD2A6DA2-1E3B-4D25-AF4A-F6637511EBBAQ34505232-85D5DCED-CCBA-47E7-A059-EF76D743199BQ34516351-799FDFB7-4211-4DF8-98AC-4C1D3C5AB1E6Q34558936-BF9C0F4B-51A3-41FF-875F-ABB2F35428C3Q34575300-D54858B1-F65D-4D7A-9BDA-30C52757CDA9Q34710843-7E6582D7-D6B7-489B-9664-1B513B26FAE7Q34720933-C3B7B0A4-8ACF-4D43-91C2-596F75F4F021Q34799877-76A5B943-F197-4E81-9206-7D1D7C08001EQ34995233-1C275554-F6FE-4504-A2B9-14365A68EA5CQ35133691-594645A1-1050-41B5-BFD3-9F8F93931949Q35531720-98F9BDC0-9E7B-47E2-B02D-FECAB1E8D9EDQ35755187-EABCFA16-1C35-4922-BEF4-C66AD166F44DQ36139922-322666DC-98A2-4148-A5DD-75D6ECB2B59BQ36166662-6B0B388E-7CD0-40C3-BC1F-A975877B962CQ36182181-B1EAC7AB-8BC0-49BC-A026-4D71AEFA66DBQ36186624-15238555-2D4E-438D-B8DD-85BB8F196F4EQ36237302-F40780AD-B35A-4E57-9BEA-4A238EA1A638Q36245354-625C84C6-92F1-4204-A8A0-D6ECD41B57D6Q36264955-0EC16FD5-ECC1-4E93-BD57-E1D34DD50239Q36276560-E29427A8-196E-461D-94D5-51BE2F5500FBQ36497321-0FCA0894-85BB-456B-BF52-A5C6FADDB297Q36876093-C75B0AD9-E6F4-435B-A840-262E50C2EAF9Q37066490-9D5122B6-EFF0-42F6-8638-DC882695E030Q37246532-605C4462-A501-4D64-83B2-D5FDE03255EC
P2860
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@ast
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@en
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@nl
type
label
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@ast
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@en
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@nl
prefLabel
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@ast
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@en
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
@en
P2093
Allen C Gao
Brandi L Cantarel
Brandi M Cantarel
Changling Li
Henry F Frierson
John Petros
Jonathan W Simons
Kristen B Otto
Robert L Vessella
P2860
P2888
P304
P3181
P356
10.1038/NG1528
P407
P577
2005-04-01T00:00:00Z
P5875
P6179
1000572024